GSK: research collaboration to evaluate coronavirus vaccine

(CercleFinance.com) - GlaxoSmithKline said that it has entered into a research collaboration with China's Clover for its protein-based coronavirus vaccine candidate.


GSK said it will provide Clover with its pandemic adjuvant system for further evaluation of its Covid-19 S-Trimer in preclinical studies.

An adjuvant is added to some vaccines to enhance the immune response, thereby creating a stronger and longer lasting immunity against infections than the vaccine alone.

With one of the largest in-house biomanufacturing capabilities in China, Clover could potentially rapidly scale-up and produce large-quantities of a new coronavirus vaccine, the British drugmaker said.

There is currently no vaccine available for Covid-19, which has infected over 76,000 people so far and has caused over 2,800 reported deaths.

Copyright (c) 2020 CercleFinance.com. All rights reserved.